Krystal Biotech Announces $10 Million Private Placement

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
50
Krystal Biotech Announces $10 Million Private Placement with Frazier Healthcare Partners

PITTSBURGH, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has entered into a securities purchase agreement with Frazier Healthcare Partners for the private placement of 625,000 shares at $16 per share. The private placement will yield gross proceeds of $10 million and is expected to close on August 17, 2018, subject to the satisfaction of customary closing conditions.

“We are extremely pleased that an impressive investor like Frazier Healthcare Partners supports our efforts to become a leader in the field of dermatological diseases,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech, Inc.

Net proceeds from this offering are expected to be used to continue funding the research and development of Krystal’s pipeline product candidates.

Chardan acted as the sole placement agent in the transaction.

The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

About Krystal Biotech Krystal Biotech, Inc. (NASDAQ: KRYS) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. For more information, please visit http://www.krystalbio.com .

Forward-Looking Statements This press release contains forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements.  Although Krystal's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Krystal, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, among others: actions by the FDA and other regulatory agencies, results and timing of current and planned clinical trials, risks related to the commercialization of our products, our ability to manufacture sufficient quantities of products for clinical trials and commercial launch, and those other risks detailed from time to time under the caption “Risk Factors” and elsewhere in Krystal Biotech's Securities and Exchange Commission (SEC) filings included in our Annual Report on Form on Form 10-K for the year ended December 31, 2017, and in future filings and reports of Krystal Biotech. The Company undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations.

INVESTOR CONTACT Ashley R. Robinson LifeSci Advisors arr@lifesciadvisors.com

MEDIA CONTACT Darren Opland LifeSci Public Relations darren@lifescipublicrelations.com

Source: Krystal Biotech, Inc.

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 177

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 231

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 459

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 23

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 54

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 46

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 373

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 142

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin’s Price Dynamics: Labor Reports and Elections Impacting Trends

Updated Category News Views 197

Labor Market Reports and Bitcoin's Future Into The Cryptoverse founder Benjamin Cowen shares insights on the current trajectory of Bitcoin as market dynamics shift with upcoming labor market reports and election results. Market Predictions Impacted by External Factors Cowen emphasizes that predictions in the short term remain complex. He notes that the momentum of the...

Continue Reading
Wearable Materials Market Forecast: Growth to USD 9.14 Billion

Updated Category News Views 238

Overview of the Wearable Materials Market The Wearable Materials Market is on an impressive trajectory, with an anticipated growth from USD 3.24 billion in 2024 to USD 9.14 billion by 2032. This surge represents a compounded annual growth rate (CAGR) of 13.85% during the forecast years. Such expansion is astonished by the increasing demand for wearables associated with...

Continue Reading
Strengthening Ties: Xi Jinping and Singaporean PM Wong Unite

Updated Category News Views 382

Strengthening Bilateral Relations for a Brighter Future In a significant meeting that highlights the growing ties between China and Singapore, President Xi Jinping recently welcomed Singaporean Prime Minister Lawrence Wong in Beijing. This engagement underscores the deepening friendship and collaboration between the two nations. During their discussions, President Xi...

Continue Reading
Exploring the Rapid Growth of the Virtual Cards Market

Updated Category News Views 154

Overview of the Virtual Cards Market The global virtual cards market is poised for substantial growth, with estimates suggesting an increase of USD 428.6 billion from 2025 to 2029. A significant annual growth rate of 17.1% during this period is projected, reflecting the ongoing transformations in the payment landscape, particularly driven by advancements in technology and...

Continue Reading
Appian Introduces Advanced AI Features to Revolutionize Workflow

Updated Category News Views 240

Transforming Business Processes with AI Appian, renowned for its innovative process automation solutions, has just rolled out significant enhancements to its platform. By embedding sophisticated AI agents into enterprise workflows, Appian is making strides in automating complex tasks, and empowering business users to revamp outdated applications seamlessly. Empowering...

Continue Reading